Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 9INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 7Tumor-Agnostic 6Thoracic 5Other solid neoplasm 3Gynecologic 2Genitourinary 2CNS 2Breast 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Head & Neck 1

Conditions

Neoplasms 1Kidney Neoplasms 1Carcinoma, Renal Cell 1Advanced Prostate Adenocarcinoma 1

Interventions

pembrolizumab 164Prednisone 130enzalutamide 127Docetaxel 122Abiraterone Acetate 95Nivolumab 93Gemcitabine 71Sunitinib 67atezolizumab 50abiraterone 50Leuprolide 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 48Cisplatin 48radium Ra 223 dichloride 39Sorafenib 39darolutamide 38apalutamide 38Ipilimumab 38Carboplatin 37Prednisolone 33Everolimus 33Axitinib 32cabozantinib 31avelumab 31pazopanib 30Bevacizumab 30Paclitaxel 29enfortumab vedotin 28bicalutamide 28Cyclophosphamide 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × cediranib × Genitourinary × Clear all
NCT00423332 2017-02-02

Cediranib (AZD2171, RECENTINâ„¢) in Metastatic or Recurrent Renal Cell Carcinoma

AstraZeneca

Phase 2 Completed
105 enrolled 12 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasms

NCT00502164 2011-01-21

AZD2171IL/0003

AstraZeneca

Phase 1 Completed
40 enrolled
Genitourinary

Advanced Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡